Original Articles Vol. 3 No. 3 (2026): Bioscience Insights Published 2026-10-16

CIRCULATING TUMOR DNA LIQUID BIOPSY IN COLORECTAL CANCER: ADVANCES IN EARLY DETECTION, MINIMAL RESIDUAL DISEASE, AND PRECISION ONCOLOGY

Authors

  • Muhammad Shoaib Rafiq Department of Pathology, The Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan Pakistan Author
  • Sehar Fatima Virology lab, Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad Punjab Pakistan Pakistan Author
  • Nadia Sarwar Virology lab, Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad Punjab Pakistan Pakistan Author
  • Ayesha Qayyum Virology lab, Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad Punjab Pakistan Pakistan Author
  • Ibtisham Elahi Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Pakistan Author
  • Muhammad Aden Virology lab, Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad Punjab Pakistan Pakistan Author
  • Umair Qaisar Department of Biochemistry, Government College University Faisalabad Pakistan Pakistan Author
  • Aqeel Murtaza Institute of Microbiology, University of Agriculture Faisalabad Punjab Pakistan Pakistan Author
  • Amna Maqsood Virology lab, Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad Punjab Pakistan Pakistan Author
  • Muhammad Yasir Malik Virology lab, Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad Punjab Pakistan Pakistan Author
38 views 24 downloads

Abstract

Colorectal cancer (CRC) remains a major global health challenge, with disease outcomes largely dependent on early detection, accurate molecular characterization and effective therapeutic management. Conventional diagnostic approaches, including colonoscopy, tissue biopsy, and imaging, are associated with limitations such as invasiveness, sampling bias, and inability to provide real-time information on tumor evolution. Circulating tumor DNA (ctDNA)-based liquid biopsy has emerged as a promising minimally invasive biotechnology approach for detecting and monitoring tumor-derived molecular alterations in blood. This review summarizes recent advances in ctDNA analysis for CRC, focusing on molecular mechanisms, analytical platforms, and clinical applications. The roles of polymerase chain reaction-based assays, digital droplet PCR, next-generation sequencing, DNA methylation profiling, and multi-omics approaches in ctDNA characterization are discussed. Furthermore, the applications of ctDNA in early cancer detection, prognosis prediction, minimal residual disease monitoring, treatment response assessment, and precision oncology are highlighted. Despite significant progress, challenges including low ctDNA abundance, tumor heterogeneity, technical variability, assay standardization, and clinical validation remain barriers to widespread implementation. Future integration of artificial intelligence, advanced sequencing technologies, and personalized molecular surveillance strategies may enhance the clinical utility of ctDNA. Overall, ctDNA-based liquid biopsy represents a promising molecular diagnostic approach with potential to transform CRC detection and personalized patient management.

Keywords

  • Colorectal cancer; circulating tumor DNA; liquid biopsy; precision oncology; molecular biomarkers; next-generation sequencing

Views & Downloads Statistics (Last 12 Months)

Monthly performance and trends of article views and downloads

Views (12 months)38
Downloads (12 months)24
Article Views PDF Downloads